Amantadine
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
* Major Indication: [[Influenza]] Infection | * Major Indication: [[Influenza]] Infection | ||
* Drug Class: [[M2 Proton Channel]] Inhibitor | * Drug Class: [[M2 Proton Channel]] Inhibitor | ||
| - | * Date of FDA Approval): 1966 | + | * Date of FDA Approval (Patent Expiration): 1966 (1986) |
* 1994 Sales: N/A | * 1994 Sales: N/A | ||
* Importance: One of the the first treatments approved by the FDA and the first approved for treatment of [[Influenza]] Infections. Nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu. Interestingly, in 1969 it was also discovered that Amantadine helped reduce the symptoms of Parkinson's Disease. | * Importance: One of the the first treatments approved by the FDA and the first approved for treatment of [[Influenza]] Infections. Nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu. Interestingly, in 1969 it was also discovered that Amantadine helped reduce the symptoms of Parkinson's Disease. | ||
Revision as of 12:16, 7 December 2010
|
Better Known as: Symmetrel
- Marketed By: Endo Pharmaceuticals
- Major Indication: Influenza Infection
- Drug Class: M2 Proton Channel Inhibitor
- Date of FDA Approval (Patent Expiration): 1966 (1986)
- 1994 Sales: N/A
- Importance: One of the the first treatments approved by the FDA and the first approved for treatment of Influenza Infections. Nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu. Interestingly, in 1969 it was also discovered that Amantadine helped reduce the symptoms of Parkinson's Disease.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| M2 Proton Channel Inhibitor Pharmacokinetics[1][2] | ||||||
|---|---|---|---|---|---|---|
| Parameter | Rimantadine | Amantadine | ||||
| Tmax (hr) | 4.3 | 2.5 | ||||
| Cmax (ng/ml) | 310 | 402 | ||||
| Bioavailability (%) | >90 | >90 | ||||
| Protein Binding (%) | 40 | 67 | ||||
| T1/2 (hr) | 27.7 | ~15 | ||||
| AUC (ng/ml/hr) | 11917 | 5420 | ||||
| Dosage (mg) | 100 | 100 | ||||
| Metabolism | Negligible | Negligible | ||||
References
- ↑ Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987 Jul;31(7):1140-2. PMID:3662473
- ↑ Wang P, Liang YZ, Chen BM, Zhou N, Yi LZ, Yu Y, Yi ZB. Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. J Pharm Biomed Anal. 2007 Mar 12;43(4):1519-25. Epub 2006 Dec 6. PMID:17156962 doi:10.1016/j.jpba.2006.10.044
